Pen testing · Digital health & life sciences
Penetration Testing for Clinical Research Organizations
Penetration testing for a CRO has to work around systems that carry a validation status your organization cannot afford to invalidate. The trigger is usually a sponsor qualification audit asking for testing evidence, a hospital site questioning remote-monitoring access, or a new eCOA rollout nobody has assessed yet. We scope testing to protect validated environments while still producing the evidence a sponsor auditor or a site's IT security team will actually accept.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What testing has to cover without breaking validation
A CRO's environment mixes systems built for strict change control with participant-facing tools that behave like any other consumer app.
Validated EDC and eTMF platforms
Systems such as Medidata Rave, Veeva CDMS or Veeva Vault carry a validation status the organization needs intact, so testing has to be scoped and scheduled to avoid triggering unplanned change control.
IRT/RTSM randomization systems
Systems controlling treatment allocation, where an unintended disruption during testing could compromise study blinding rather than just system uptime.
eCOA and ePRO applications on participant devices
Software running on tablets and phones outside a controlled office environment, where the attack surface includes the device itself, not just the backend.
Remote-monitoring access paths into site EHRs
The authentication and session-handling around read-only monitor accounts into hospital systems, an access route the site treats as an extension of its own network.
Regulatory map
Why testing evidence matters to two different audiences
A sponsor auditor and a hospital site security reviewer are checking for different things, and a single generic test report rarely satisfies both.
GCP vendor qualification expectations
Sponsor qualification audits flowing from Division 5's good clinical practice requirements increasingly expect documented security testing as part of vendor due diligence, alongside the trial-conduct evidence QA already provides.
PIPEDA's safeguards expectation
PIPEDA expects safeguards proportionate to the sensitivity of the personal information involved, and testing evidence is one of the more concrete ways an organization demonstrates that its safeguards actually work.
The US business-associate context
Even where a CRO is not a business associate under US rules, sponsor MSAs often import HIPAA-grade safeguard expectations, and testing evidence is frequently the artifact that satisfies them.
What goes wrong
What testing finds before a sponsor or an inspector does
The findings that matter most in this environment are rarely the generic ones a template pen test checklist would surface.
Access-control gaps in remote-monitoring accounts
Weak session handling or missing multi-factor authentication on monitor logins into hospital EHRs — an issue a hospital site security review treats as urgent even if a sponsor audit barely mentions it.
Exposed eCOA or ePRO endpoints
Participant-facing applications with weaker authentication than the internal EDC, since the assumption that 'it's just a survey' rarely survives real testing.
Data exposure through file exchange with sponsors and labs
Unsecured transfer paths for sponsor-confidential protocols or central-lab sample manifests, where a finding is a contract issue as much as a technical one.
The scenario the sector's defining outage exposed
The 2020 ransomware attack on eResearchTechnology pushed hundreds of trials onto pen and paper, and testing that includes ransomware-relevant paths — remote access, backup isolation — speaks directly to what sponsors now ask about.
Our pen testing for clinical research organizations
What our penetration testing covers for a CRO
Testing scoped to your actual eClinical stack, with a process built to avoid disrupting validated systems.
Scoped testing of non-validated infrastructure
Corporate network, file exchange platforms and internal tools tested with standard methodology, kept separate from anything carrying a formal validation status.
Coordinated testing of validated systems
Where EDC, eTMF or IRT testing is required, we plan timing, scope and rollback with the organization's validation lead so testing does not itself become a change-control event.
eCOA and ePRO application assessment
Testing of participant-facing applications and the APIs behind them, covering the device-side attack surface a backend-only test would miss.
Remote-monitoring access review
Assessment of how monitor credentials authenticate into site EHRs, including session handling and offboarding, for organizations whose sites are asking questions.
Dual-format reporting
Findings written up in a form a sponsor's qualification audit can absorb quickly, and a separate summary suited to a hospital site's own security review.
How the engagement runs
How testing runs alongside active studies
Scheduling and scope are set to avoid interfering with live trial operations.
Step 1
Scoping with your validation lead
We identify which systems are validated, which are not, and what testing activity would trigger unplanned change control before any testing begins.
Step 2
Testing execution
Testing runs in a defined window, coordinated with study teams to avoid active data-collection periods or scheduled monitoring visits.
Step 3
Findings review
Results are reviewed with IT and QA together, so remediation priorities reflect both technical severity and any GCP validation implications.
Step 4
Reporting for each audience
We deliver the sponsor-facing report and, where relevant, a separate summary formatted for a hospital site's own IT security reviewers.
What it costs
What drives penetration testing cost for a CRO
Cost depends on how many systems are in scope, whether validated environments require special coordination with your validation lead, and whether eCOA or ePRO applications need device-level testing alongside the backend. A study running only internal EDC access looks very different from one involving remote monitoring, a Phase 1 unit's systems and a participant-facing app all at once.
Retesting cadence usually follows sponsor audit cycles and major platform changes rather than a fixed annual date, so the cost conversation includes when your next qualification audit or new study go-live is expected. Get a tailored quote once we understand your current systems inventory.
Clinical Research Organizations: Pen testing questions, answered
Yes, with careful scoping and coordination with whoever owns validation for that system. Testing is planned around the change-control process so it does not itself count as an unplanned modification, and any finding that requires a fix is remediated through the normal validated-change path rather than an ad hoc patch.
Sponsor audits generally want evidence that testing happened, what was found, and how it was remediated, mapped loosely to GCP vendor qualification expectations. Hospital sites tend to focus narrowly on the remote-monitoring access path itself, wanting proof that a monitor's credentials cannot be used to reach anything beyond what was authorized.
Yes. An eCOA or ePRO app running on a participant's personal phone has a different threat model than an internal tool, and its authentication is often weaker than the systems your team assumes are the priority.
Retest ahead of known sponsor qualification audits and after any significant platform change, rather than sticking to a strict annual schedule. A CRO with staggered sponsor relationships often ends up testing more frequently than a single-product company simply because the audit calendar is busier.
Testing is scoped to avoid handling live sponsor-confidential data directly wherever possible, using test accounts and non-production data instead. Where production systems must be tested, the clinical trial agreement's confidentiality terms are reviewed first so the testing approach stays inside what the sponsor has authorized.
The test has to respect the hospital's own security boundaries, since the monitor account is technically inside the site's system, not just yours. Findings are reported with the site's IT security review in mind, because that is often the audience that ends up reading them.
More for clinical research organizations
Other services for this niche
- Privacy & security for clinical research organizations — overview
- Virtual CISO
- Virtual Privacy Officer
- Incident Response Planning
- Privacy & Security Policy Development
- Privacy & Security Training
- Vendor Security Review & Questionnaire Support
- SOC 2 Readiness
- ISO 27001 Readiness
- AI Privacy Impact Assessment
- HIPAA Readiness
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.